for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allergan plc

AGN.N

Latest Trade

186.37USD

Change

0.29(+0.16%)

Volume

382,938

Today's Range

186.23

 - 

186.88

52 Week Range

114.27

 - 

186.90

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
186.08
Open
186.40
Volume
382,938
3M AVG Volume
49.95
Today's High
186.88
Today's Low
186.23
52 Week High
186.90
52 Week Low
114.27
Shares Out (MIL)
328.28
Market Cap (MIL)
61,181.05
Forward P/E
11.00
Dividend (Yield %)
1.59

Next Event

Q4 2019 Allergan plc Earnings Release

Latest Developments

More

Allergan Announces Positive Phase 3 Achieve I Trial Results For Ubrogepant Published In New England Journal Of Medicine

Third Point Reports Share Stake In Afya Ltd, SmileDirectClub

Exicure And Allergan Enter Collaboration, Option And License Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allergan plc

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.

Industry

Biotechnology & Drugs

Contact Info

Clonshaugh Business And Technology Park

+353.21.65235000

https://www.allergan.com/

Executive Leadership

Brenton L. Saunders

Chairman of the Board, President, Chief Executive Officer

Matthew M. Walsh

Chief Financial Officer, Executive Vice President

Karen Lee Ling

Chief Human Resource Officer, Executive Vice President

A. Robert D. Bailey

Executive Vice President, Chief Legal Officer and Corporate Secretary

William J. Meury

Executive Vice President, Chief Commercial Officer

Key Stats

2.74 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

14.6K

2017

15.9K

2018

15.8K

2019(E)

15.8K
EPS (USD)

2016

13.510

2017

16.350

2018

16.690

2019(E)

16.937
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.87
Price To Book (MRQ)
1.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
38.52
LT Debt To Equity (MRQ)
32.13
Return on Investment (TTM)
-10.01
Return on Equity (TTM)
-9.21

Latest News

Latest News

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

AbbVie Inc <ABBV.N> on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc <AGN.N>.

AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie Inc <ABBV.N> said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc <AGN.N>.

Allergan settles Alzheimer's therapy lawsuit for $750 million

Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer's disease therapy Namenda, the drugmaker said, in a resolution to the litigation that was set to face trial on Monday.

Allergan settles Alzheimer's therapy lawsuit for $750 million

Allergan Plc said on Monday it had settled a class action lawsuit brought by a group of direct purchasers of Alzheimer's disease therapy Namenda, resolving the litigation that was set to face trial this month.

FTC requests AbbVie, Allergan for more information on $63 billion deal

The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc <ABBV.N> and botox maker Allergan Plc <AGN.N> on their $63 billion deal, the companies said on Friday.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's <ABBV.N> planned $63 billion purchase of Botox maker Allergan...

Drugmakers Endo, Allergan agree to $15 million in settlements in major opioid case

Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.

Evolus says launch of its Botox rival ahead of its expectations

Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc <AGN.N>, which is being bought by AbbVie Inc <ABBV.N> for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc <ABBV.N> said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc <AGN.N> will counter declining sales of its long-time bestseller, Humira.

Allergan recalls textured breast implants worldwide

Allergan Plc said on Wednesday it was recalling its Biocell textured breast implants and tissue expanders across markets, citing concerns over a rare form of cancer, after the U.S. health agency asked the drugmaker to pull the products.

Allergan recalls textured breast implants across markets

Allergan Plc said on Wednesday it was recalling Biocell textured breast implants and tissue expanders across all markets following the updated safety information from the U.S. Food And Drug Administration.

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion (£49.6 billion), giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent...

US STOCKS-Wall St dragged down by Iran tensions, trade worries; Fed in focus

* Indexes down: 0.21%, S&P 0.41%, Nasdaq 0.75% (Changes comment, adds details, updates prices)

AbbVie nears deal to buy Allergan for more than $60 bln - WSJ

AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than $60 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall its textured breast implants from the Canadian market, after the country's health regulator suspended the company's licenses for its Biocell implants, citing increased risk of cancer.

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, making it a treatment option for a full spectrum of the condition's cyclical symptoms, the company said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up